Microbot Medical (MBOT) Liabilities and Shareholders Equity (2010 - 2026)

Microbot Medical has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $78.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 152.71% year-over-year to $78.1 million; the trailing twelve-month figure through Mar 2026 stood at $274.5 million (up 453.82% YoY), and the FY2025 full-year result was $81.5 million, up 1252.08% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $78.1 million, down from $81.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $81.8 million in Q3 2025, with the low at $5.2 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $23.9 million across 5 years, with a median of $9.5 million in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 62.39% — and 2025, when it soared 1469.89%.
• Microbot Medical's Liabilities and Shareholders Equity stood at $9.5 million in 2022, then decreased by 12.69% to $8.3 million in 2023, then fell by 27.57% to $6.0 million in 2024, then surged by 1252.08% to $81.5 million in 2025, then fell by 4.27% to $78.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $78.1 million (Q1 2026), $81.5 million (Q4 2025), and $81.8 million (Q3 2025), per Business Quant data.